Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gardasil 9 vaccination in surgical treatment of CIN lesions
2018-002764-94Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Feb 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of recombinant human papillomavirus 9-valent vaccine in cervical intraepithelial neoplasia (CIN), human papillomavirus infection and cervical neoplasm (2 arms), sponsored by Erasmus MC. Primary endpoint: Recurrence of CIN II–III at 24 months. Started Feb 2019; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infectioncervical neoplasm
Beyond the preview
Go deeper on 2018-002764-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002764-94.